logo
Plus   Neg
Share
Email

Sanofi Launches Phase 3 Trials To Evaluate Isatuximab In Multiple Myeloma

Sanofi (SNYNF) announced the company has launched two new late-stage clinical studies to determine if isatuximab (an anti-CD38 antibody), when used in combination with other commonly used cancer treatments, might be an effective treatment option for certain people with multiple myeloma, a rare blood cancer.

IKEMA study is a 325-patient randomized, open-label, global multicenter Phase 3 trial that will compare isatuximab in combination with carfilzomib and dexamethasone against carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma that have previously been treated with one-to-three lines of therapy.

IMROZ study is a 425-patient randomized, open-label, global multicenter Phase 3 trial that will compare isatuximab in combination with bortezomib, lenalidomide and dexamethasone against bortezomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients not eligible for transplant.

The company said both studies will evaluate progression-free survival as the primary endpoint. Key secondary endpoints include overall survival, overall response rate, depth of response, safety and quality of life.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
eBay Inc. has filed a lawsuit against Amazon.com Inc., accusing its e-commerce rival of illegally poaching sellers on its marketplace by infiltrating eBay's internal messaging system. The lawsuit filed by eBay on Wednesday in Santa Clara County in California, accuses Amazon of having "perpetrated a scheme to infiltrate and exploit eBay's internal member email system" over the past several years. Philip Morris International Inc. (PM) announced, for the third-quarter, reported and adjusted diluted earnings per share was $1.44, up 13.4% versus $1.27 in 2017. Excluding unfavorable currency of $0.09, adjusted diluted earnings per share up by 20.5% to $1.53 from $1.27 in 2017. On average, 13 analysts... Shares of Novartis AG were gaining around 2 percent in the morning trading in Switzerland after the drug major on Thursday lifted its fiscal 2018 net sales guidance, despite weak profit in its third quarter. Core earnings topped analysts' estimates, while net sales missed their view, despite a growth. Further, Novartis announced an agreement to buy Endocyte, a US-based biopharmaceutical company.
Follow RTT